Suspected neurological toxicity after oral application of fluralaner (Bravecto®) in a Kooikerhondje dog

• Main Authors: Daniela Gaens, Christoph Rummel, Martin Schmidt, Melanie Hamann, Joachim Geyer
• Format: Article
• Language: English
• Published: BMC 2019-08-01
• Series: BMC Veterinary Research
• Subjects: Bravecto; Fluralaner; Dog; Adverse drug reaction; Neurological toxicity; MDR1 mutation
• Online Access: http://link.springer.com/article/10.1186/s12917-019-2016-4

Abstract Background Although the new isoxazoline drug fluralaner (Bravecto®) is generally well tolerated in dogs, adverse drug reactions involving neurological dysfunction occurred in individual dogs. However, most of these cases are documented inadequately and none of them is reported and discussed in the literature. As isoxazoline drugs target neuronal chloride channels with a clear preference for invertebrates, they are considered to have a good safety profile. However, pharmacodynamic effects in the nervous system of vertebrates cannot be ruled out completely. Case presentation A seven-month-old female Kooikerhondje dog was treated with Bravecto® at the recommended dose. About 24 h after administration, the dog exhibited signs of neurological toxicity, including generalized ataxia, myoclonic jerks, tremor of head and body, muscle twitching and oral dysphagia. All symptoms were transient and the dog fully recovered without any treatment after 10 h. Conclusion This case report describes transient occurrence of neurological dysfunction after administration of Bravecto®. It may help to better classify adverse drug reactions after application of isoxazoline drugs and documents a good prognosis even after occurrence of severe neurological dysfunction in the present case.